AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), read with SEBI Circular No. SEBI/HO/MIRSD/MIRSD_RTAMB/P/CIR/2022/8 dated January 25, 2022, kindly note that the Company has issued the Letter of Confirmation in lieu of Duplicate Share Certificate AARTI DRUGS LTD. - 524348 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we hereby inform you that the Company has received information from Link Intime India Private Limited, Registrar & Share Transfer Agent of the Company for Loss of share certificates AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the provisions of Regulation 30(6) of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we would like to inform you that the officials of the Company will be meeting Investors/Analysts (Participants) AARTI DRUGS LTD. - 524348 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Please find enclosed herewith the Annual Secretarial Compliance Report of the Company issued by Sunil M. Dedhia & Co., Company Secretaries in Practice, for the financial year ended March 31, 2022. AARTI DRUGS LTD. - 524348 - Compliance Under Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.
In terms of Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions in the format specified under SEBI Circular bearing reference no. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021, for the half year ended March 31, 2022. AARTI DRUGS LTD. - 524348 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Please find attached herewith transcript of Q4 FY22 Earning Conference call. AARTI DRUGS LTD. - 524348 - Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company AARTI DRUGS LTD. 2 CIN NO. L37060MH1984PLC055433 3 Report filed for FY 2021-2022 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* FY 2021-22, 2022-23 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)FY 2020-21, 2021-22 Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Rushikesh DeoleDesignation :-Company Secretary and Compliance Officer Name of the Chief Financial Officer :- Adhish P Patil Designation : -Chief Financial Officer Date: 13/05/2022 AARTI DRUGS LTD. - 524348 - Recording Of Conference Call
In continuation to our letter dated May 5, 2022 regarding intimation of Investors/ Analyst conference call on the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2022, we would like to inform you that the audio recording of the said call has been uploaded on the Company's website. This can be accessed via the following link. Link: https://www.aartidrugs.co.in/concalls-transcript/ Q4FY22 Quarterly Result Announced for Aarti Drugs Ltd.
Pharmaceuticals firm Aarti Drugs declares Q4FY22 result: Q4FY22 consolidated revenue grew 39% YoY Q4FY22 API revenue and volume grew by 46% and 23%, respectively Specialty chemicals, intermediates & others continued the robust momentum Consolidated Financial Highlights – Q4 FY22 Revenue stood at Rs 697.2 crores as against Rs 502.7 crores, a growth of 39% YoY. EBITDA stood at Rs 89.0 crores as against Rs 81.9 crores YoY. EBITDA Margin (%) came in at 12.8%. PAT stood at Rs 55.3 crores as against Rs 51.6 crores YoY. PAT Margin (%) stood at 8.0%. Consolidated Financial Highlights – FY22 Revenue stood at Rs 2,500.0 crores as against Rs 2,159.3 crores, up 16% YoY. EBITDA stood at Rs 340.8 crores as against Rs 441.6 crores YoY. EBITDA Margin (%) came in at 13.7%. PAT stood at Rs 205.0 crores as against Rs 280.4 crores YoY. PAT Margin (%) came in at 8.2%. Commenting on the results Mr. Adhish Patil, Chief Financial Officer – Aarti Drugs Limited said, “The company reported resilient set of performance with improved product mix even though the entire globe continued to face unparalleled challenges in the business environment. The company posted robust revenue growth of 39% in Q4FY22, which was primarily driven by 46% YoY growth in API business along with 17.0% in Specialty Chemicals, Intermediates & Others. EBITDA and PAT grew by 9% and 7%, respectively. EBITDA and EBITDA margins were mainly affected due to continuous inflationary pressure on input costs. The company’s FY22 revenue stood at Rs 2,500 crores, a growth of 16% YoY. The improved product mix and better operating leverage partially offset the higher raw material costs. As communicated earlier, EBITDA margins and profitability is not exactly comparable on a YoY basis due to elevated API margins during FY21 on account of Covid-19 related disruptions. The growth trajectory in the API segment is expected to accelerate further in the upcoming quarters driven by recently commissioned anti-diabetics facility, ongoing expansion and backward integration. The company continued the healthy pace of growth in Specialty Chemicals and Intermediates both for Q4 and FY22. The company’s presence in niche chemistry along with strong R&D; skills is expected to drive the growth momentum further. Formulation segment revenue stood at Rs 69.0 crores for the quarter, a growth of 11% YoY. The formulation segment contributed ~10% to the consolidated revenue for the quarter. Exports continues to be a key focus area for the formulation segment. ~39% of the revenue came from exports during the quarter. On a consolidated level, the ongoing geopolitical conflicts, continuous inflationary pressure on manufacturing costs, China lockdown induced supply chain disruptions coupled with sharp upward movement in crude oil prices affected the margins and profitability. The company has undertaken multiple price hikes during the quarter to partially offset the impact. However, these price hikes weren’t sufficient as the velocity and volatility of increase in input costs remained very high. The company expects normalisation in the margins once the input prices stabilise which we expect by the end of Q2FY23. Result PDF
